Theriva Biologics, Inc. (TOVX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for the period ended March 31, 2026. Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, primarily developing its lead oncolytic adenovirus candidate, VCN-01 (zabilugene almadenorepvec), for pancreatic cancer and retinoblastoma. The Company also holds assets in gastrointestinal diseases, including SYN-004 and SYN-020, though it is actively seeking to out-license non-oncology assets to preserve capital.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $300,000 | $0 |
| Net Loss | $(2,044,000) | $(4,324,000) |
| Net Loss Per Share | $(0.05) | $(1.55) |
| Cash and Cash Equivalents | $14,431,000 | $10,014,000 |
| Accumulated Deficit | $(360,754,000) | $(339,295,000) |
| Operating Cash Flow | $(2,456,000) | $(4,756,000) |
| Financing Cash Flow | $3,866,000 | $3,072,000 |
Debt and Liabilities: Total liabilities were $22.8 million. This includes a significant contingent consideration liability of $10.0 million related to the acquisition of VCN Biosciences, with $1.2 million classified as current. The Company holds approximately $1.7 million in loans payable from Spanish government programs.
Material Changes vs. Prior Period
- Revenue Recognition: The Company recognized $300,000 in license revenue from a new agreement with Rasayana Therapeutics for the SYN-020 asset, compared to zero revenue in Q1 2025.
- Expense Reduction: Research and Development (R&D) expenses dropped 88% to $355,000 from $2.97 million, driven by the completion of the VIRAGE Phase 2b trial and the recognition of a Spanish R&D tax credit rebate. General and Administrative (G&A) expenses increased 43% to $2.1 million due to higher legal and investor relations costs.
- Capital Raise: The Company raised approximately $2.3 million in net proceeds through its At-The-Market (ATM) offering by selling over 10 million shares. Additionally, it received $1.6 million in cash from a Spanish government R&D rebate.
- Workforce Restructuring: In September 2025, the Company reduced its workforce by 32% (7 employees) to extend its cash runway, incurring approximately $520,000 in charges.
Guidance, Outlook, and Risks
Going Concern: The filing includes a "substantial doubt" disclosure regarding the Company's ability to continue as a going concern for the next 12 months without additional capital. Management estimates current cash ($14.4 million) will fund operations into the first quarter of 2027, but only for specific, limited activities.
Strategic Focus:
- VCN-01 (Oncology): The Company received FDA agreement on a Phase 3 trial design for metastatic pancreatic cancer. It plans to commence a small Phase 2a feasibility study in H2 2026 to test repeat dosing. It is also pursuing regulatory interactions for a pivotal retinoblastoma trial.
- SYN-004 (GI): The Company does not intend to fund further development of SYN-004 internally and is seeking a partner or licensee. The last cohort of its Phase 1b/2a trial will not commence without external funding.
- SYN-020 (GI): Successfully out-licensed to Rasayana Therapeutics for an upfront payment of $300,000, with potential for up to $38 million in milestones and royalties.
Key Risks:
- Liquidity: Failure to secure additional financing could force the cessation of development activities. A deferred milestone payment of $5.0 million to Grifols (related to the VCN acquisition) remains outstanding and could significantly deplete cash reserves if paid.
- Regulatory: Future clinical trials and commercialization depend on FDA/EMA approvals, which are uncertain.
- Strategic Alternatives: The Company is exploring mergers, reverse mergers, or business combinations, but there is no assurance these will be completed on favorable terms.
Investor Verification Checklist
- Cash Runway: Verify the specific burn rate and confirm if the "Q1 2027" runway estimate accounts for the potential $5.0 million Grifols milestone payment.
- ATM Capacity: Confirm the remaining capacity under the At-The-Market (ATM) Sales Agreement, noting SEC limitations based on public float.
- VCN-01 Phase 3 Timeline: Monitor the initiation of the proposed Phase 2a feasibility study in Spain (expected H2 2026) as a prerequisite for the Phase 3 trial.
- Contingent Consideration: Review the status of negotiations regarding the deferred $5.0 million milestone payment to Grifols.
- Strategic Review: Track any announcements regarding the strategic alternatives review (mergers/acquisitions) mentioned in the risk factors.